Cannatrek and RYAH Medtech Inc. to provide Australian patients with dose-measuring inhalers and cartridges

By June 9, 2020product
Cannatrek and RYAH Medtech Inc. to provide Australian patients with dose-measuring inhalers and cartridges

Australian ‘seed-to-patient’ medicinal cannabis enterprise Cannatrek Ltd announced today it will soon receive the first shipment of dose-measuring inhalers and medicinal cannabis cartridges for Australian patients, imported from New York-based technology and predictive analysis company RYAH Medtech Inc.

Cannatrek, which first entered a partnership with RYAH Medtech in October 2019, will shortly be able to provide dry-herb inhaler devices and cartridges to patients in Australia.

Dose-measuring inhalers provide an excellent, user-friendly way of administering correct doses of medicinal cannabis, overcoming shortfalls inherent in manual dosing. Cannatrek’s vertically integrated system will soon cover all operations in the medicinal cannabis industry, from the cartridge-filling process to distribution to the final patient.

‘We’re extremely excited to expand our global presence by launching RYAH with such an incredible brand as Cannatrek,’ says Jordan Medley, Director of Product Operations of RYAH. ‘Cannatrek’s commitment to excellence is what makes them a trusted leader in the Australian market, and knowing that both of our companies’ world-class products will work together to give patients in Australia the best possible treatment options is a very special thought for our entire team.’

Cannatrek CEO Tommy Huppert said the dose-measuring inhalers and cartridges were a key step in developing a digital health platform that will provide the Australian medical industry with insightful data. This in turn will lead to better medical outcomes for patients with illnesses including chronic pain, anxiety, movement and sleep disorders.

‘Cartridges and dose-measuring inhalers provide patients with fixed, repeatable doses of medicinal cannabis,’ he said. ‘They represent a much better delivery system than manual delivery. Importantly, dose-measuring technology accurately measures the volume inhaled with each draw and allows to track usage statistics.’

Mr Huppert said the technology represented a game-changer in terms of digital health, data collection and patient care. ‘Importantly, data collected can later be used for multiple clinical trials in the future. The medicinal cannabis industry needs data, and any way we can assist the gathering of data is important and helpful. We can support doctors and help them to find appropriate doses and strains for different patients and different medical conditions.’